{"id":6752,"date":"2021-12-01T15:08:32","date_gmt":"2021-12-01T15:08:32","guid":{"rendered":"https:\/\/haugpartners.com\/article\/xryem-pharmaceutical-settlement-acceleration-clause-found-anticompetitive-due-to-risk-of-profit-crushing-competition-2\/"},"modified":"2024-09-26T09:05:46","modified_gmt":"2024-09-26T09:05:46","slug":"xryem-pharmaceutical-settlement-acceleration-clause-found-anticompetitive-due-to-risk-of-profit-crushing-competition-2","status":"publish","type":"article","link":"https:\/\/haugpartners.com\/article\/xryem-pharmaceutical-settlement-acceleration-clause-found-anticompetitive-due-to-risk-of-profit-crushing-competition-2\/","title":{"rendered":"<i>Xryem<\/i>: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of \u201cProfit Crushing Competition\u201d"},"featured_media":5605,"template":"","categories":[98],"acf":[],"_links":{"self":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/article\/6752"}],"collection":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/article"}],"about":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/types\/article"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/media\/5605"}],"wp:attachment":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/media?parent=6752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/categories?post=6752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}